The addition of zoledronic acid to aromatase inhibitors is associated with improved bone mineral density, but not with an effect on clinically-meaningful end points such as fractures. The oncology community should prioritize the design of trials evaluating more relevant end points, such as fragility fracture risk, for treatment-induced bone loss and critically assess the effects of such treatment on breast cancer survival.
References
Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60–62 (2005).
Brufsky, A. M. et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z.-FAST study 36-month follow-up results. Clin. Breast Cancer 9, 77–85 (2009).
Eidtmann, H. et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res. 69, 74S (American Association for Cancer Research, 2009).
Lombarto, A. et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Proc. American Soc. Clinical Oncology 213 (American Society of Clinical Oncology, 2009).
Seeman, E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 4 1, 308–317 (2007).
Forbes, J. F. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45–53 (2008).
Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691 (2009).
Coleman, R. et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Cancer Res. 69, 733S (American Association for Cancer Research, 2009).
Ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875–4882 (2008).
Woodward, E. J. et al. Five year efficacy in cancer survivors of a single dose of zoledronic acid 4 mg in osteopenia and annual dosing in osteoporosis. The IX International Meeting on Cancer Induced Bone Disease (Cancer and Bone Society, 2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Robert Josse declares he is on the speaker's bureau for, and gets grant/research support from, Amgen and Novartis. Mark Clemons declares he is on the speaker's bureau for, and gets grant/research support from, Amgen and Novartis. Eitan Amir, Alberto Ocaña and Bostjan Seruga declare no competing interests.
Rights and permissions
About this article
Cite this article
Amir, E., Ocaña, A., Seruga, B. et al. Zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev Clin Oncol 7, 187–188 (2010). https://doi.org/10.1038/nrclinonc.2010.19
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.19
- Springer Nature Limited